INDEX TO VOLUME 174

Author Index

Abe, M., 318
Abou-El-Magd, I., 157
Abramson, O., 1271
Abrego, P., 1341
Abrutyn, E., 537
Acosta, E. P., 673
Acosta, L. P., 163
Adam, R. D., 233
Adler, S. P., 387
Agace, W., 1080
Agterberg, C., 89
Aguayo, N., 944
AIDS Clinical Trials Group Protocol 116A/116B/117 Team, 696
AIDS Clinical Trials Group 116B/117 Study Team and ACTG Virology Committee Resistance and HIV-1 RNA Working Groups, 704
Aiello, P., S223
Ait-Khaled, M., 396
Aiyama, T., 1316
Åkerlund, B., 324
Albritton, W. L., S176
Alexiou-Daniel, S., 407
Alfieri, A., S30
Ali, N., 654
Aligui, G. D. L., 163
Alonso, P. L., 367
Alter, H. J., 690
Alves, D., 1021
Alving, C. R., 361
Ampel, N. M., 440
Amundson, D., 537
Andersen, L. P., 544
Anderson, L. J., 456
Anderson, R. M., S150
Andersson, J., 324
Andersson, S., 977
Anding, P., 1309
Angarano, G., 447
Antoniadis, A., 407
Aral, S. O., S127, S201
Arcoleo, F., 1051
Armstrong-Schellenberg, J. R. M., 367
Arvin, A. M., 249, 899, 1162
Asanuma, H., 444
Ashley, R., 470
Ashraf, A. B., 184
Asselot, C., 606
Astemborski, J. A., 299
Atherton, J. C., 552
Aubin, J-T., 668
Aurelius, E., 324
Awadzi, K., 380
Back, D., 671
Bagasra, O., 1101
Baier-Bitterlich, G., 677
Bailey, R. E., 346
Bailey, R. L., 643
Baker, C. J., 332
Balis, F., 16
Balish, E., 133, 589
Ballou, W. R., 361
Balzarini, J., 962
Banerji, S., 141
Baquero, F., 1015, 1345
Barbeau, P., 969
Bardin, C., 188
Barnes, G. L., S22
Barnes, P. F., 431
Barniak, V., S88
Barrett, L. K., 647
Barrios, C., 583
Barry, C. E., III, 1085
Barry, M., 671
Barsig, J., 790
Baruch, A. C., 233
Barvir, D. A., 1176
Baseler, M., 63
Basombrio, M. A., 944
Bastie, A., 1
Bauhofer, A., 790
Baum, M., 1101
Bavari, S., 338
Baxa, D. M., 401
Beam, T. R., Jr., 537
Beardsley, L., 679
Bégaud, E., 1124
Begg, N., 1360
Bell, L. M., S73
Belmatoug, N., 414
Belshe, R. B., 113
Bendtzen, K., 557
Benedetti, J., 1058
Bennett, S., 1091
Benson, M., 1080
Bergamini, A., 214
Berger, B. J., 659
Bermudez, L. E., 574, 1218
Bernard, N., 969
Bernasconi, S., 1098
Bernier, R. H., S118
Bernstein, D. I., 668
Berti, E., 668
Bertolli, J., 722
Bertozzi, S. M., S253
Besser, T. E., 276
Best, J. M., 237
Bestetti, G., 668
Bettinardi, A., 181
Betts, R. F., 838
Bhan, M. K., 768, S30
Bhandari, N., 768
Biberfeld, G., 977
Bible, J. M., 237
Bienzle, U., 1320
Bierman, R., 679
Bigoni, B., 669
Bingen, E., 520
Binks, M. H., 654
Bishop, R. F., S22
Bitzan, M., 1028
Black, R. E., 268
Blaser, M. J., 552, 1046
Bläuer, F., 651
Blázquez, J., 1015
Bleton, R., 414
Bloom, B. J., 623
Bloom, B. R., 431
Bobroski, L. E., 1101
Boeckh, M., 907
Boerger, P., 361
Bohidar, N., 1271
Böhler, T., 244
Boiocchi, M., 669
Bonneville, M., 969
Booy, R., 878
Borcherding, W. R., 1143
Borian, F. E., S73
Borleffs, J. C. C., 34
Borrow, R., 1360
Borvak, J., 850
Bosmans, E., 913
Böttger, E. C., 354
Boucher, C. A. B., 845
Boucher, J., 606
Bourne, N., 668
Bowden, R. A., 907
Bowler, W. A., 249
Boylen, C. T., 431
Bradley, S., 537
Brambilla, L., 668
Brandell, A., 324
Brandt, M. E., 812
Brattig, N. W., 1309
Breiman, R. F., 456, 986
Brew, B. J., 294
Brichacek, B., 1191
Briggs, J. D., 177
Briles, D. E., 884
Bron, D., 913
Brooks-Walter, A., 884
Brouwers, P., 16, 1200
Brown, B. A., 354
Brown, C., 722
Brown, D., S12
Brown, E. G., 619
Brown, J. A., 1303
Brown, M., 8
Brummer, E., 888
Brunner, G. D., 828
Brunton, J., 1279
Bryan, T., 1185
Bryant, G. L., 739
Bryson, Y., 713
Buchbinder, S. P., 954
Buckland, J., 937
Bucklin, S. E., 1249
Bugg, H. C., S22
Buisman, A.-M., 417
Bukh, J., 1324
Bundschuh, D. S., 790
Burchett, B. M., 240
Burchett, S. K., 1162
Burk, R. D., 679
Burke, R. L., 387
Burrous, J. M., 1176
Burt, J.-A., 1279
Busch, M. P., 26
Buseyne, F., 734
Bush, C. E., 401
Bustamante, C., 1341
Butler, J. C., 986
Butron, B., 268
Byrne, G. E., 1101
Byrne, W. R., 537
Cabral, L., 1101
Cadeo, G., 181
Calcagno, G., 199
Callister, S. M., 739
Campbell, A. E., 643
Campbell, L. A., 893
Campos, J., 1345
Cantey, R., 537
Cantinieaux, B., 800
Cantón, R., 1015, 1345
Cantorna, M. T., 747
Cao, B.-L., 346
Cao, G. L., 1001
Caporale, D. A., 221
Capozzi, M., 214
Cappannoli, L., 214
Capra, M., 668
Carbon, C., 414
Carbone, A., 669
Carmack, M. A., 899
Carr, A., 195

Carron, J.-C., 969
Carter, J. J., 927
Cartwright, K., 1360
Casey, J. L., 920
Cason, J., 237
Cassai, E., 669
Cataldo, P. T., 199
Cates, W., Jr., S127
Cavalli, B., 892
Cegielski, J. P., 675
Centra, M., 1001
Cerami, A., 659
Cetron, M. S., 986
Chamberlin, C. J., 249
Chang, F.-Y., 1116
Chang, S. Y., 899
Chanock, R. M., S65
Charboneau, D., 507
Charlebois, E. D., 1105
Chast, F., 188
Chen, D.-S., 173, 410
Chen, P.-J., 173, 410
Chen, S. C., S93
Chen, W., 410
Cheng, Y., 1112
Cheung, L., 690
Chi, W.-K., 173
Chian, H.-M., 173
Chiang, B.-L., 173
Chiba, S., 444
Chong, S., 8
Chou, C.-S., 850
Chou, T.-C., 672
Chougnet, C., 46
Chow, A. W., 1261
Christen, H.-J., 421
Christensen, N. D., 927
Christian, L., 440
Chu, Y.-D., 173
Church, J., 16
Cillari, E., 1051
Cinque, P., 1098
Clark, D. A., 396
Clark, H. F., S73
Clarke, M. J., S5
Clarke, R. C., 1021
Clerici, M., 46
Coffey, T. J., 884
Cogniaux, J., 962
Cohen, A. J., 615
Cohen, M. S., S223
Cohn, S., 690
Colebunders, R., 862
Colletti, P., 1051
Colodny, S. M., 1116
Colopy, M. W., 249
Colucci, M., 1255
Comar, M., 204
Compans, R. W., S1, S3
Conly, J., 1279
Conner, M. E., S88
Connick, E., 483
Constans, J., 969
Contorni, M., 1168
Conway, B., 191
Conway, D. J., 643
Coombs, R. W., 696, 704
Cooper, D. A., 195
Cooper, E. R., 1207
Corbellino, M., 668
Corey, L., 1162, 470
Cork, L., 1279
Corry, D. B., 440
Corsaro, B., S88
Cort, S., 713
Costes, O., 404
Coutinho, R. A., 862
Cover, T. L., 552
Cowan, F. M., 470
Coyle, S. M., 1356
Craig, A. A., 373
Crain, M. J., 884
Craven, R. B., 346
Crawford, S., S88
Crémieux, A.-C., 414
Crociati, A., 1098
Cross, A. S., 537
Crumpacker, C. S., 696, 704
Cryptococcal Disease Active Surveillance Group, 812
Cryz, S. J., Jr., 537
Cuervas-Mons, V., 583
Dabis, F., 969
Dagan, R., 1271, 1352
D'Agostino, P., 1051
Dai, W. W., 659
D'Andrea, V. M., 1176
Daniel, B. L., 163
Dankert, J., 246
Dankner, W. M., 288
D'Aquila, R. T., 696, 704
Darthuy, F., 1
Das, B. K., S30
Daskalopoulos, G., 631
Davey, R. T., Jr., 63
David, F., 874
David, J. R., 1131
David, R. A., 1131
Davidson, B. L., 268
Davis, C. B., 463
Davis, S. L., 435
De Clercq, E., 913, 962
Decosas, J., S248
Dedier, H., 1279
Deepe, G. S., Jr., 828
de Groot, R., 120
DeGruttola, V., 704
de Jong, M. D., 845
del Corral, H., 1131
de Lellis, L., 669
Delforge, A., 913
del Palacio, A., 583
De Maddalena, C., 892
Demeter, L., 696
DeMuri, G. P., 127
Demuth, S. G., 463
Denamur, E., 520
Dennis, D. T., 346
Dény, P., 606
de Paoli, P., 204
Derouin, F., 874
Desai, M., 500
Deschênes, J., 393
Des Jarlais, D. C., 309
Desmyter, J., 962
Devalck, C., 800
de Veyra, F., 163
Dhumeaux, D., 1
Diallo, M. O., 446
Diaz, C., 1207
Dib, O. P., 821
DiCicco, R., 463
Dick, E. C., 1143
Di Luca, D., 669
Dimock, K., 619
Dings, M. E. M., 34
Di Stefano, M., 447
do Carmo, T. M. A., 1131
Doit, C., 520
Dolan, G., 1091
Dolcetti, R., 669
Dolin, R., 696
Domingo, E., 163
Donovan, R. M., 401
Donta, S. T., 537
Dorrell, L., 862
dos Reis, M. G., 1131
Douglas, J. M., Jr., 954
Dowell, S. F., 456
Drabik, G., 256
Drabinski, D., S88
Drlica, K., 1127
Dronda, F., 891
Dube, D. K., 944
Dube, S., 944
Dubois, D. R., 1176
DuChateau, B. K., 739
Dukes, C. S., 675
Duliège, A.-M., 387
Dunbar, N., 294
Duncombe, C., 195
Dupon, M., 969
DuPont, H. L., 676
Duval, J., 1
Duval, P., 1124
Dworkin, M. S., 663, 1372
Dworkin, R. H., 239
Dyas, B., 338
Dziarski, R., 777
Earhart, K. C., 242
Eckels, K. H., 1176
Edwards, M. S., 332
Efstratiou, A., 500
Eiden, J. J., S73
Eiffert, H., 421, 424, 1108
El-Hawey, A. M., 157
Eliasson, A. H., 537
Elion, J., 520
Ellermann-Eriksen, S., 557
Elliott, J. A., 986
Ellis, R. W., S73
Ellison, R. T., III, 537
Elliston, D., 537
Ellner, J. J., 727, 806
Elsborg, L., 544
El-Yousef, M., 8
Emerson, S. U., 1324
Emery, V. C., 396
Endepols, S., 1108
Engel, A. M., 1320
Engle, R. E., 920
English, B. K., 638, 1348
Enwere, G., 1091
Epstein, M. P., 97
Erdman, D. D., 456
Escobar, H., 1345
Esparza, B., 891
Estabrook, M. M., 760
Esteban, E., 944
Estes, M. K., S37, S88
Euler-König, I., 209
Evans, M. J., 8
Everitt, D. E., 463
Excler, J. L., 734
Facklam, R. R., 986
Faggioli, E., 214
Fairley, C. K., 1360
Falloon, J., 63
Farley, M., 16, 1200
Farrington, C. P., S12
Farzadegan, H., 299, 1332
Federal Hyperimmune Immunoglobulin Trial Study Group, 537
Fekade, D., 627
Feng, N., S47
Fernandez, F. M., S98
Ferrario, G., 786
Ferrer, J. F., 944
Ferster, A., 800
Fevidal, P., 163
File, T. M., Jr., 456
Finlayson, R., 195
Fiordalisi, G., 181
Fiore, J. R., 447
Fischl, M., 696
Fitzgerald, J., 8
Fleer, A., 636
Fletcher, C. V., 673
Fleury, B., 734
Flock, J.-I., 83
Flynn, P. M., 490
Foggia, M., 199
Fondu, P., 800
Font, F., 367
Fothergill, A. W., 821
Fowler, M. G., 1207
Fox, A. J., 1360
Franchini, G., 977
Franco, M. A., S47
Freedman, D. O., 380
Freels, S., 309
Frenkel, J., 1091
Fridland, A., 490
Frottier, J., 283
Fuchs, D., 677

Fukuda, K., 309
Fumarola, D., 1255
Fynan, E. F., S93
Gaastra, W., 768
Gafford, G., 537
Galagan, D. M., 1143
Galai, N., 309
Galanos, C., 1040
Galgiani, J. N., 440
Galli, M., 668, 892
Gallo, D., 858
Galloway, D. A., 927
Galluzzo, A., 1051
Gambino, G., 1051
Gamble, H. R., 663
García, C., 1345
Garcia, M., 1279
Garnett, G. P., S150
Garry, L., 414
Gary, D. W., 219
Gary, H. E., Jr., 456
Gay, N. J., S12
Gaydos, C. A., 895
Geiss, M., 244
Gentry, M. J., 225
Gentsch, J. R., S5, S30
George, L. K., 240
George, R., 500
Georgiou, M., 1345
Geretti, A. M., 34
Gerin, J. L., 920
Germani, Y., 1124
Gern, J. E., 1143
Geslin, P., 520
Ghosh, K., 1380
Ghys, P. D., 446
Giacca, M., 204
Gianotto, M., 892
Gibbons, R., 828
Gil, A., 268
Gilquin, J., 188
Giordano, C., 1051
Giuliani, G., 1255
Glass, A. G., 937
Glass, R. I., S1, S3, S5, S30
Glesby, M. J., 1332
Glimcher, L. H., 1303
Goeman, J., 862
Goldenthal, K. L., S112
Goldman, D. P., 1372
Goldman, M., 994
Goldsmith, J., 16
Gomez, F. J., 828
Gomez, H., 920
Gómez-Lus, R., 1345
Gong, J.-h., 431
Gordon, D. M., 361
Gorrell, R. J., S22
Gough, J., 427
Goulston, C., 858
Gouvea, V., 8
Gow, I. R., 862
Graber, J., 309
Graham, N. M. H., 299
Graviss, E. A., 812
Gray, G. C., 835
Grayston, J. T., 893
Greenberg, D., 1271
Greenberg, D. P., 752
Greenberg, H. B., S47, S93
Greenberg, S. J., 8
Greenwood, B., 1091
Greer, C. E., 937
Gregory, S. H., 1073
Greiner, S., S88
Grewal, H. M. S., 768
Griffin, G., 627
Griffin, G. E., 54
Griffiss, J. M., 537
Griffiths, P. D., 396
Gross, M., 361
Grossin, M., 414
Grundy, J. E., 1151
Guerrant, R. L., 451
Guinea, A., 598
Gujral, S., 888
Gulati, S., 1223, 1238
Gumpert, B., 537
Gupta, D., 777
Gutiérrez, M., 891
Guyot, C., 606
Gyles, C. L., 1021
Haakenson, C., 537
Haas, J., 244
Hadler, S., S118
Haeder, M., 881
Hahn, B. L., 1369
Hajjeh, R. A., 812
Haley, L., 191
Hall, T., 361
Halverson, C. W., S230
Hamadeh, R., 537
Hamill, R. J., 537
Hamilton, J. D., 240
Hammerschlag, M. R., 895
Hanson, C., 1207
Hanson, C. V., 858
Hanson, D. L., 1212
Harkins, J., 249
Harmsen, M. C., 444
Harn, D. A., Jr., 1131
Harrell, L. J., 1010
Harrington, W. J., Jr., 1101
Harris, M., 26
Hartskeerl, R. A., 874
Hartung, T., 790
Hashemi, F. N., 529
Hawdon, J., 1380
Hawes, S. E., 1058
Hawkins, E. P., 435
Hayden, M. K., 529
Hayes, C. E., 747
Hayes, P., 54
Hayes, R., 367
Hazell, S. L., 631
He, B., 262
He, Q., 1288
Hegenscheid, B., 1320
Heifets, L., 354
Heimdahl, A., 83
Heinkelein, M., 209
Hellström, M., 1080
Hemenway, L. S., 752
Hempfling, S., 387
Hempson, S. J., 1328
Henchal, L. S., S112
Henderson, G. E., S223
Hengst, J., 944
Henrard, D., 26
Henry, K., 673
Heppner, D. G., 361
Herman, S., 26
Hermann, D., 1040
Hermans, P., 962
Herrin, V. E., 835
Herrmann, J. E., S93
Hershow, R., 1207
Hershow, R. C., 309
Herwaldt, B. L., 1372
Herzyk, D. J., 463
Hess, G., 1320
Hewlett, I. K., 1185
Hickey, M. J., 1085
Hienz, S. A., 83
Higgins, K. W., 866
Hillier, S. L., 1058
Hirayama, K., 1131
Hirsch, M. S., 672
Ho, G. Y. F., 679
Ho, M. S., S5
Hodge, W. G., 393
Hoekman, K., 120
Hoffenberg, E., 8
Hoffmann, J. W., 75
Hofmann, J., 986
Hoft, D. F., 113
Hoggard, P., 671
Hoke, C. H., 1176
Hol, C., 636
Holck, S., 544
Holland, M. J., 643
Holman, R. C., S5
Holmes, D. W., 221
Holmes, K. K., 1058, S127, S230
Holodniy, M., 854
Holsboer, F., 1040
Hooper, C., 704
Hoover, D. R., 690, 1332
Hoover, R., 937
Hop, W. C. J., 120
Hopkins, H. A., 69
Horsburgh, C. R., Jr., 1212
Hoshino, Y., S65
Hostetter, M. K., 127
Hotez, P., 1380
Hotsubo, T., 444
Hsiang, S.-C., 410
HTLV Spanish Study Group, 891
Hu, B., S88
Huang, W., 26
Huapaya, A., 268
Hubbert, N., 937
Huijmans, J. G. M., 120
Hunninghake, G. W., 69, 262
Hurt, N., 367
Hwang, L.-H., 173
Hyams, J., 8
Hyams, K. C., 920
Ikeda, H., 318
Ilson, B., 463
Imrie, A., 195
Inderlied, C. B., 1218
Intrieri, M., 199
Isaac-Renton, J., 233
Ishikawa, T., 1316
Ivanoff, B. N., S1
Iwata, K., 1316
Iyer, D., 431
Jackson, J. B., 696, 704, 727
Jackson, L. A., 893
Jacobs, R. F., 1162
Jacobs, S. L., 1116
Jacobson, M. A., 219, 1105
Jaffar, S., 1091
Jakeman, K. J., 674
Jani, D. B., 1223
Janoff, E. N., 244, 1191
Janvier, G., 734
Japour, A. J., 696, 704
Jara, P., 583
Jassoy, C., 209
Jelinek, T., 1376
Jellinger, R. M., 448
Jelonek, M. T., 866
Jensen, J., 133
Jensen, J. R., 739
Jett-Goheen, M., 268
Jiang, B., S88
Jiang, X., 1073
Jin, S., S5
Jin, Y-P., 777
Jobe, D. A., 739
Jodal, U., 1080
Joensuu, J., S81
John, J. F., Jr., 537
Johnson, A. M., 470
Johnson, B. J. B., 346
Johnson, C., 133, 537
Johnson, D. W., S230
Johnson, J. A., 1364
Johnson, J. L., 727, 806
Johnson, R. P., 1021
Johnson, V. A., 696, 704
Jones, D. M., 1360
Jones, J. L., 1212
Jones-Carson, J., 589
Jönsson, S., 1080
Jorgensen, M., 631
Jorkasky, D. K., 463
Joseph, B., 1143
Joshi, B. H., 1185
Journot, V., 969
Judson, F. N., 954
Julander, I., 324

Just, M., 1288
Kahn, J., 704
Kahn, J. O., 696
Kain, K. C., 373
Kakumu, S., 1316
Kaldor, J., 195, 294
Kalish, L. A., 1207
Kamenga, M., 722
Kao, J.-H., 173, 410
Kapikian, A. Z., S65
Kaplan, G., 105
Kaplan, J. E., 309
Kaplan, S. L., 435
Karmali, M. A., 1021
Kasahara, K., 564
Kasai, T., 318
Kasama, T., 564
Kaslow, R. A., 1120
Katsura, T., 564
Katz, D. R., 654
Katz, M. H., 954
Katzenstein, D., 854, 858
Kauffman, C., 537
Kaufmann, S. H. E., 1309
Kaul, R., 1279
Kauppi-Korkeila, M., 1337
Käyhty, H., 1337
Kazatchkine, M. D., 188
Keller, A., 16
Keller, M. A., 866
Kelly, G., 63
Kelly, J. W., 537
Kemp, E. B., 113
Kennedy, C., 1279
Keogh, C. V., 994
Kessler, H. A., 46
Keys, T. F., S230
Khabbaz, R., 309
Khan, A. S., 1185
Khoo, S., 671
Kidd, I. M., 396
Kieny, M. P., 734
Kilama, W. L., 367
Kilgore, P. E., S5
Kimberlin, D. W., 1162
King, R., 427
Kirkpatrick, W. R., 821
Kirnbauer, R., 238, 937
Kitsuwannakul, S., 870
Kitua, A. Y., 367
Kiviat, N., 927
Klein, R. S., 309
Klempner, M. S., 97
Klinker, H., 209
Kloth, M., 1028
Kobayashi, J. M., 1372
Kobayashi, K., 564
Koeuth, T., 760
Kohl, S., 1105
Kombarova, S. Y., 1064
Koopmans, P. G., 610
Kootstra, N. A., 845
Kornelisse, R. F., 120
Korth, C., 1040
Koutsky, L. A., 927, 1058
Kovacs, J. A., 63
Krah, D., S73
Krajden, M., 1279
Krausa, P., 643
Krause, D. S., 896
Kreiswirth, B. N., 1085, 1127
Kruszon-Moran, D., 1120
Krzych, U., 361
Kum, W. W. S., 1261
Kumar, R., S30
Kuo, C.-C., 647, 893
Kuritsky, J. N., S118
Kuritzkes, D. R., 483, 696, 704
Kuypers, J., 219, 927
Kvale, P. A., S230
Kwiatkowski, D., 1091
Kwok, S., 288, 696, 704
Labigne, A., 1046
Lacombe, E. H., 221
Lafeuillade, A., 404
Laga, M., 446
Lagneaux, L., 913
Lagos, R., 1341
Lai, M.-Y., 173
Lakeman, F. D., 1162
Lakey, D. L., 838
Lalonde, R. G., 393
Lampropoulos, A., 407
Lamson, M., 713
Lanata, C. F., 268
Landay, A. L., 46
Lane, H. C., 63
Lane, J. R., 1200
Lang, D. R., 451, S1, S3
Lange, J. M. A., 845, 862
Langermans, J. A. M., 417
Laochumroonvorapong, P., 105
LaRocco, A., 249
Lasry, S., 606
Laufs, R., 881
Law, M., 195
Lazzarin, A., 1098
Leaf, H., 537
Le Bouguénec, C., 1124
Lee, S., 1185
Lee, S.-K., 927
Lee, S.-Y., 173
Lee, T.-H., 26
Lefrère, J. J., 283
Leite, J. P., S30
Leitner, W., 361
Lejeune, M., 800
Lempa, M., 679
Leroux, M-C., 606
Levin, M., 878
Levine, M. M., 675, 1341
Levine, O. S., 1341
Lewis, L. L., 16
Liguory, O., 874
Limbach, K., 977
Lin, Y.G., 431
Lior, H., 1021
Lipson, S. M., 184
Livartowski, A., 606
Locksley, R. M., 440
Logigian, E. L., 623
Lorincz, A. T., 937
Löscher, T., 1376
Losonsky, G. A., 1341, 1364
Lovrich, S. D., 739
Lowry, S. F., 994, 1356
Lowy, D., 238, 937
Loza, E., 1015
Ludwig, K., 1028
Lumbreras, C., 583
Lund, J. S., S22
Lupski, J. R., 760
Luzuriaga, K., 713
Mabey, D. C. W., 643
MacCormac, L. P., 1151
Mack, D., 881
Mack, P., 256
MacQueen, K. M., 954
Madore, D., 1337
Madore, H. P., S88
Mahe, V., 188
Mäkitalo, B., 977
Mancino, G., 214
Mandrell, R. E., 1223
Mannheimer, S. B., 513
Manoff, S. B., 299
Manos, M. M., 238, 937
Mansueto, S., 1051
Mantero, G., 181
Mantovani, A., 1098
Marchant, A., 994
Margolick, J. B., 1332
Mårild, S., 1080
Marimoutou, C., 969
Mariotti, M., 283
Markowitz, N. P., 401
Marone, P., 786
Marra, C. M., 219
Marston, B. J., 456
Martin, D. H., S230
Masanja, H., 367
Masendycz, P. J., S22
Maskrey, J. L., 866
Mason, E. O., Jr., 435
Mastronarde, J. G., 262
Masur, H., 63
Match, M. E., 184
Mathewson, J. J., 676
Matos, E. P., 1131
Matsushima, K., 262
Matter, H. C., 1288
Matuschka, F.-R., 421, 424, 1108
Matushek, M. G., 529
MaWhinney, S., 483
Mayer, L. W., 346, 812
Mazurova, I. K., 1064
McAtee, R. K., 821
McCarthy, J. S., 1384
McCarthy, M., 920
McClain, J. B., 537
McCloskey, R. V., 63
McCloud, B., 97
McCordic, R., 1348
McCruden, E. A. B., 177
McDaniel, L. S., 884
McEwen, S. A., 1021
McKinney, N., 288
McKirnan, D. J., 954
McLaren, C., 696
McQuillan, G. M., 1120
McQuillen, D. P., 1223, 1238
McSherry, G., 713
Mdluli, K., 1085
Meals, E., 638
Mehra, V., 431
Meier, A., 354
Meier-Osusky, I., 651
Meijer, D. K. F., 444
Melamed, R., 1271, 1352
Melcher, G. P., 46, 537
Mellencamp, M. A., 507
Memming, H., 1091
Mendelman, P. M., 1271
Mendez, H., 1207
Mendoza, E. C., 842
Menendez, C., 367
Merigan, T., 854
Merigan, T. C., 448
Merino, F., 891
Merrill, D. P., 672
Mertsola, J., 1288
Métreau, J.-M., 1
Meynard, J. L., 283
Meyohas, M. C., 283
Midthun, K., 268, S112
Milano, S., 1051
Millan, C., 184
Miller, R. F., 141, 654
Mindel, A., 470
Mitchell, H. M., 631
Miyashiro, D., 529
Mocciaro, C., 1051
Moldawer, L. L., 1356
Mole, L., 854
Molina, J.-M., 874
Møller, B., 557
Monath, T. P., 256
Monick, M. M., 69, 262
Monno, L., 447
Montaner, J. S. G., 191
Montemurro, P., 1255
Mooi, F., 89
Moran, A. P., 1255
Morandi, M., 1168
Moreau, J.-F., 969
Moreno, E., 583
Morita, K., 318
Morosini, M. I., 1015
Morris, J. G., Jr., 1364
Morris, S., 1085
Morris, S. R., 221
Morrison, D. A., 884
Morrison, D. C., 1249
Moses, S., S240
Mosley, J. W., 26

Moye, J., 1207
Msengi, A. E., 675
Muallem, M., 1271, 1352
Mueller, B., 16
Mueller, B. U., 1200
Mugerwa, R. D., 727
Mukaida, N., 262
Müller-Wiefel, D. E., 1028
Mulligan, M., 537
Mullington, J., 1040
Mullins, J. I., 858
Munk, M. E., 1309
Muñoz, A., 299
Munro, J., 177
Muolo, V., 1255
Musser, J. M., 1127
Nabavi, N., 1303
Nadel, S., 878
Nahm, M. H., 75
Nakao, H., 1064
Nash, K. A., 1218
Nasio, J., 427
Nataro, J. P., 1364
National Cancer Institute Pediatric Branch Human Immunodeficiency Virus Working Group, 16
National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, 1162
Ndinya-Achola, J. O., 427
Negri, M. C., 1015
Negussie, Y., 627
Neijens, H. J., 120
Neill, M. A., 1136
Nelson, K. E., 690, 870
Nemeth, A., 8
Newport, M. J., 878
Ngugi, E. N., S240
Nichol, S. T., 407
Nichols, S., 288
Nicolas, J.-C., 606
Nieburg, P., 722
Nielsen, H., 544
Nikkari, S., 1288
Niro, G. A., 920
Nocton, J. J., 623
Nonnenmacher, B., 937
Nørgaard, A., 544
Noriega, A. R., 583
Noring, R., 97
Nothdurft, H. D., 1376
Nsubuga, P., 727
Nugent, R. P., 1207
Nuijens, J., 444
Numazaki, K., 444
Nutman, T. B., 1384
Obel, N., 557
Oette, D., 727
O'Farrell, N., 445
Offit, P. A., S59, S73
Ohlenbusch, A., 421, 424, 1108
Ohya, O., 318
Okumura, A., 1316
Okwera, A., 727
Olander, J. V., 75
Oldfield, E. C., III, 249
Olds, G. R., 163
Olveda, R. M., 163
Onyiorah, E., 1091
Operskalski, E. A., 26
O'Reilly, K. R., S214
Orenstein, W. A., S118
Oriani, G., 199
Orlicek, S. L., 638, 1348
Orth, A., 1040
O'Shaughnessy, M. V., 191
Osterhaus, A. D. M. E., 34
Ottesen, E. A., 598
Ou, C.-Y., 722
Over, M., S162
Paciorkowski, A., 659
Padian, N. S., S127, S176, S182, S188
Padilla, M. L., 739
Paglieroni, T. G., 842
Palmer, A., 1091
Pane, F., 199
Panigrahi, P., 1364
Paoletti, E., 734, 977
Papa, A., 407
Papp, J. R., 1296
Paraninfo, G., 181
Park, M. K., 75
Parravicini, C., 668
Parsons, S., S88
Patou, G., 862
Patrick, C. C., 1348
Patterson, T. F., 821
Patton, D. L., 647
Paul, S., 105
Pawlotsky, J.-M., 1
Paya, C. V., 583
Pece, S., 1255
Pedneault, V., S248
Peduzzi, P., 537
Peek, R. M., Jr., 552
Peeling, R. W., 643
Peeters, M., 89
Pellegrin, J.-L., 969
Pemberton, L., 294
Penny, M. E., 268
Penny, R., 195
Peralta-Ramos, M., 944
Pérez-Pérez, G. I., 1046
Pérez-Schael, I., S19, S65
Pergolizzi, R., 184
Peri, G., 1098
Persing, D. H., 623
Perversi, L., 786
Peters, C. J., 407
Peters, M., 679
Peters, P. A., 163
Petersen, C. M., 557
Petrofsky, M., 1218
Pezzotti, P., 309
Pfaller, M. A., 812
Pialoux, G., 734
Piazza, M., 199
Picard, B., 520
Piccoli, C., 1255
Piccoli, D., 8
Pichichero, M., S73
Picken, M. M., 1112
Picken, R. N., 1112
Pieper, C. F., 240
Piglansky, L., 1271, 1352
Piketty, C., 188
Pinner, R. W., 812
Piot, P., S162, S214
Pirruccello, S., 1191
Piscitelli, S. C., 63
Pitt, J., 1207
Pizzo, P. A., 16, 1200
Pizzuto, M., 668
Placido, R., 214
Plier, D. A., 380
Plotkin, S. A., 387, S73
Plouffe, J. F., 456
Plummer, F., 427
Plummer, F. A., S240
Pneumococcal Sentinel Surveillance Working Group, 986
Poggi, C., 404
Poiesz, B. J., 944
Poirel, L., 668
Poli, G., 1098
Polis, M. A., 63
Pollmächer, T., 1040
Pomerantz, R. J., 1101
Popovic, T., 1064
Porter, T. G., 361
Potterat, J. J., S144
Potts, B. J., 866
Powell, D. A., 1162
Pratt, R. D., 288
Preheim, L. C., 225
Prigge, W., 507
Primi, D., 181
Prober, C. G., 899, 1162
Profizi, N., 404
Pugliese, A., 786
Purcell, R. H., 1324
Putkonen, P., 977
Putnak, R., 1176
Quartararo, P., 1051
Quinn, J. P., 529
Quinn, T., 722
Quinn, T. C., 895
Raboud, J. M., 191
Ragnaud, J.-M., 969
Rahn, K., 1021
Ramachandran, M., S30
Ramilo, O., 850
Ramirez, B. D. L., 163
Ramos, E. A. G., 1131
Ramsay, M., S12
Rand, P. W., 221
Ratych, R. E., 1001
Rauzy, M., 606
Ravdin, J. I., 157
Rayment, N., 654
Redding, S. W., 821
Reed, G., 838
Rees, J., 812
Reeves, M. W., 1064
Rehg, J. E., 229
Reichelderfer, P. A., 696
Reichelderfer, P. S., 704
Reichman, R., 696
Reinert, P., 606
Reis, E. A. G., 1131
Reller, L. B., 1010
Remick, D. G., 627
Rémiré, J., 1
Rennels, M. B., S107
Renwick, S. A., 1021
Revankar, S. G., 821
Rezza, G., 309
Ribner, B., 537
Rice, E. W., 1364
Rice, P. A., 1223, 1238
Rich, E. D., 276
Richards, R. L., 361
Richiusa, P., 1051
Richman, D. D., 696, 704
Richter, D., 421, 424, 1108
Rickinson, A., 324
Riepenhoff-Talty, M., 8
Riley, L. W., 513
Rinaldi, M. G., 821
Rivière, Y., 734
Rizzardi, G. P., 54
Rizzo, R. T., 299
Robb, M. L., 1200
Robbins, B., 490
Robbins, K. E., 346
Roberts, R. B., 513
Robertson, M. N., 734
Robinson, H. L., S93
Robinson, J., 713
Roblin, P. M., 895
Rocchi, G., 214
Rodman, J. H., 490
Rogers, R. A., 97
Román, F., 1345
Romulo, R., 163
Ronald, A., 427
Rosberg, S., 1080
Rosen, G. M., 1001
Rosenwirth, B., 850
Rossi, T., 8
Rost, J. R., 1010
Rothenberg, R. B., S144
Roudot-Thoraval, F., 1
Rubin, M., 16
Rubins, J. B., 507
Rückle-Lanz, H., 209
Ruder, H., 1028
Ruffin, D., 8
Rusnak, J., 46
Rutledge, B. J., 623
Ryan, M. J., S12
Saah, A. J., 1332

Saarinen, L., 1337
Sacchetti, L., 199
Sachs, D. H., 26
Sacks, S. L., 476
Sadoff, J., 537
Sadoff, J. C., 361, 1176
Saif, L. J., S98
St. Louis, M. E., 722
Salanitro, A., 214
Saldana, F., 899
Saleh-Mghir, A., 414
Salmon-Céron, D., 242
Salvatore, F., 199
Sampalis, J., 393
Sander, P., 354
Sandhu, K. S., 1021
San Martin, O., 1341
Sannella, E., 838
Santhanagopalan, V., 1369
Santoro, J. C., S93
Saravolatz, L. D., 401
Sarfati, C., 874
Sariban, E., 800
Sasadeusz, J. J., 476
Sauer, A., 790
Sawanpanyalert, P., 870
Sawyer, M. H., 249
Sayre, K., 944
Schaffner, A., 651
Schäkel, K., 8
Schalén, C., 636
Schechter, M. T., 191
Schein, R. M. H., 537
Schell, R. F., 739
Schellekens, J., 89
Schennings, T., 83
Schiappa, D. A., 529
Schiffman, M. H., 238, 937
Schiller, J., 238, 937
Schlichtemeier, R., 483
Schlüter, V., 1320
Schmader, K. E., 240
Schmid, C. H., 623
Schmidt-Schläpfer, G., 1288
Schmit, J.-C., 962
Schneemann, M., 651
Schneider, G., 1091
Schneider, I., 361
Schoedon, G., 651
Schoel, B., 1309
Schols, D., 913
Schooley, R. T., 483
Schreiber, W., 1040
Schuitema, A. R. J., 874
Schuitemaker, H., 845
Schultsz, C., 246
Schwebke, K., 673
Scott, D. R., 937
Scott, G., 713
Sebstad, J., S240
Secor, W. E., 1131
Segovia, A., 944
Sei, S., 1200
Semeraro, N., 1255
Shafer, R. W., 448
Shahabuddin, M., 1185
Sharon, J., 1238
Shattock, R. J., 54
Shaw, A. R., S73
Shaw, R. D., 1328
Shearer, G. M., 16, 46
Shenep, J. L., 1348
Shepp, D. H., 184
Sher, A., 46
Sherlock, C., 191
Sherman, D. R., 1085
Sherman, M. E., 937
Shewen, P. E., 1296
Shiboski, S., S188
Shih, J. W., 690
Shimamura, T., 564
Shiratsuchi, H., 806
Siemssen, N., 881
Sigaroudinia, M., 1105
Simonds, R. J., 722
Simonelli, C., 204
Sjöström, M., 1080
Slagle, D., 537
Sloas, M., 16
Smeaton, L. M., 696
Smeriglio, V., 1207
Smith, C. W., 435
Smith, G. E., 838
Smith, J. C., S5
Smith, K. Y., 529
Smith, R., S88
Smith, R. P., Jr., 221
Smith, T. A., 367
Snijders, F., 246
Snitily, M. U., 225
Snoeck, R., 913
Sohnle, P. G., 1369
Soike, K., 256
Sokol, R. J., 8
Solomon, L., 299
Soman, G., 256
Sommerfelt, H., 768
Soong, C.-J. G., 157
Soriano, V., 891
Sosa, C. E., 1101
Sozzani, S., 1098
Spector, S. A., 288
Speranza, F., 786
Spielman, A., 421, 424, 1108
Spika, J. S., 1021
Spinelli, A., 1051
Spiropoulou, C. F., 407
Spitzer, E. D., 812
Spooner, K. M., 63
Spratt, B. G., 884
Sprecher, S., 962
Sreevatsan, S., 1127
Staat, M. A., 1120
Stanberry, L. R., 668
Stanley, J., 500
Stark, K., 1320
Starr, S. E., 1162, 387
Stassi, G., 1051
Stechenberg, B., 713
Steel, C., 598
Steere, A. C., 623
Steigbigel, R. T., 615
Steimer, K. S., 866
Steinsland, H., 768
Stellini, R., 181
Stevens, C. E., 1058
Stevens, D. A., 888
Stevens, E., 858
Stevens-Ayers, T., 907
Stevenson, M., 1191
Stewart, S. K., 1200
Stoler, A., 214
Storgaard, M., 557
Stout, J. E., 1116
Stover, C. K., 1085
Stram, D. O., 26
Strle, F., 1112
Stryckmans, P., 913
Stylianakis, A., 407
Sukhai, R. N., 120
Sullivan, J., 529
Sullivan, J. L., 713
Sun, Y., 75
Suskin, M., 659
Svanborg, C., 1080
Svennerholm, A.-M., 768
Svensson, L., 8
Sviat, S. L., 346
Swart, P. J., 444
Sweeney, Y. T. C., 647
Sweet, C., 674
Swiatlo, E., 884
Swindells, S., 1191
Sydney Primary HIV Infection Study Group, 195
Sylvester, D. R., 361
Sztein, M. B., 1364
Tacket, C. O., 1364
Takayanagi, M., 1316
Tamalet, C., 404
Tanna, A., 500
Tanner, M., 367
Tantawichien, T., 574
Tarande, M., 722
Tarone, R. E., 238, 937
Tarr, P. I., 1136
Tartaglia, J., 734, 977
Taupin, J.-L., 969
Taylor, R. M., 1001
Tchamouroff, S. E., 862
Tennican, P. O., 663
Tenser, R. B., 667
Texier-Maugein, J., 969
Tham, K. T., 552
Thauvin, M., 283
The, T. H., 444
Thiberge, J.-M., 1046
Thomas, D. L., 690
Thomas, J. C., S134
Thompson, J., 838
Thompson, K., 463
Thompson, S. E., III, 1212
Thomssen, R., 421
Thorstensson, R., 977
Tirelli, U., 204
Titus, R. G., 1303
Tiu, E., 163
Todd, J., 696, 704
Tomaru, U., 318
Torre, D., 786
Torri, W., 1098
Traina-Dorge, V., 256
Tran, C., 899
Transmission Safety Study Group, 26
Traquina, P., 1168
Treanor, J. J., 838, S73
Trenholme, G. M., 529
Trofa, A., 361
Tsolaki, A. G., 141
Tucker, M. J., S134
Turrión, V. S., 583
Tuset, C., 891
Tynell, E., 324
Uherova, P., 483
Uhnoo, I., 8
Ulrich, P., 659
Ulrich, R. G., 338
Underwood, A. P., 141
Uthayakumar, S., 862
Vaccher, E., 204
Vadheim, C. M., 752
Vago, L., 1098
Vallejo, J. G., 332
van Alphen, L., 1337
van Baalen, C. A., 34
Vandamme, A.-M., 962
van der Heijden, A. J., 120
van der Poll, T., 1356, 994
van der Straaten, P. J. C., 120
van der Zee, A., 89
Van Dijk, H., 636
Van Dijke, E. E. M., 636
Van Dyke, G., 850
van Els, C. A. C. M., 34
van Furth, R., 417
van Hensbroek, M. B., 1091
Van Nest, G., 1168
Vannier, A. M., 752
Van Remoortel, B., 962
van't Wout, A. B., 845
Van Vaeck, C., 962
Van Voorhis, W. C., 647
Vazquez-Torres, A., 589
Veenstra, J., 845, 862
Vega, A., 920
Venkataprasad, N., 806
Ventura, G., 268
Ventura, L., 214
Venzon, D., 16
Verduin, C. M., 636
Verhoef, J., 636
Vesikari, T., S81
Viboud, G. I., 768
Vicenzi, E., 1098
Vildé, J.-L., 242

Viljanen, M. K., 1288
Vinjé, J., 610
Visser, J. J., 120
Vitale, G., 1051
Vitek, C., 309
Vitetta, E. S., 850
Vittinghoff, E., S176, S182
Vizzard, J., 195
Vlahov, D., 299, 309, 690
Volk, A., 414
Wachsmuth, I. K., 1064
Wachter, H., 677
Wagner, R. D., 589
Wakefield, A. E., 141
Wakisaka, A., 318
Walker, R. E., 63
Wall, P. G., S12
Wallace, M., 537
Wallace, M. R., 242, 249
Wallace, R. J., Jr., 354
Wallis, R. S., 727
Wang, J. B., 387
Wang, J.-T., 173
Wang, S., S93
Warburton, V., 631
Ward, J. I., 752
Ward, L. A., 276
Ward, R. L., S51
Warner, T., 133, 589
Wasserheit, J. N., S201
Wasserman, S. S., 1341
Watts, D. M., 920
Weber, J. N., 862
Weinberg, G. A., 241
Weinstein, R. A., 529
Weiss, S. M., 895
Wellde, B., 361
Weller, I. V. D., 862
Welles, S. L., 696, 704
Wells, T. G., 1372
Welsh, C. H., 537
Weltzin, R., 256
Wen, X. L., 1101
Wendel, A., 790
Wenger, J. D., 1064
Wettergren, B., 1080
Whalen, C., 727
Wharton, M., 1064
Wheeler, S., 16
Whitley, R. J., 1162
Whittle, H. C., 643
Wideroff, L., 238, 937
Wiest, P. M., 163
Wijnholds, F. J., 34
Wilkins, J. A., 427
Wilkinson, B. E., 838
Williams, I. G., 862
Wilson, D., S240
Wilson, J. B., 1021
Wing, E. J., 1073
Winters, M., 854
Winters, M. A., 448
Wipf, G. C., 927
Wirtz, R. A., 361
Witvrouw, M., 962
Wolf, S. F., 564
Wølner-Hanssen, P., 1058
Women and Infants Transmission Study Group, 1207
Wood, C., 1101
Wood, J. A. O., 1261
Wood, L., 16
Wood, M., 324
Woodhouse, D. E., S144
Woods, C. R., 760
Woods, P. A., S5, S30
Woody, J. N., 63
Wright, K. E., 619
Wright, P. F., 838
Wynn, T. A., 46
Xerry, J., 500
Xu, C., 1127
Yagupsky, P., 1271, 1352
Yamasita, I., 318
Yamazaki, J., 564
Yanagi, M., 1324
Yanai, H., 870
Yang, P.-M., 173
Yao, Q.-y., 324
Yasukawa, L. L., 899
Yen-Lieberman, B., 696
Yoshiki, T., 318
Yoshioka, K., 1316
Young, E. J., 537
Young, L. S., 574, 1218
Yu, V. L., 1116
Yuen, G., 16
Zafrani, E.-S., 1
Zaidi, A. K. M., 1010
Zanella, I., 181
Zangwill, K. M., 752
Zanussi, S., 204
Zarlenga, D. S., 663
Zarley, C. D., S88
Zarrilli, F., 199
Zehender, G., 892
Zeldis, J. B., 842
Zhang, B., 1001
Zhang, J.-Y., 256
Zhang, Y., 354
Zhaori, G., 8
Zheng, H., S223
Zimmermann, S., 1028
Zimon, A. E., 1131
Zorrilla, C., 1207
Zuckerman, R., 309

Subject Index

1-ribosylpyridin-4-one-3-carboxamide, serum concentration, as predictor of HIV disease progression, 199
β-mercaptoethylamine, inhibition of HIV-1 replication, in vitro, 214
β_2-microglobulin, in CSF, AIDS dementia complex, predictive marker for, 294
Acinetobacter baumannii, infection, outbreak, in critical care unit, 1279
Acrodermatitis chronica atrophicans lesion, in Lyme disease, etiology, 421
AIDS (*See* human immunodeficiency virus type 1 infection)
AIDS Clinical Trials 076, zidovudine use during pregnancy, pattern, 1207
AIDS dementia complex, predictive markers for, 294
Amplicor HIV-1 monitor assay, in HIV infection, variability in plasma RNA levels, 191
Ancylostoma caninum, vaccine, mouse model, 1380
Animal model
  A. caninum vaccine, mouse model, 1380
  B. pertussis infection, IL-12 and IFN-γ effect, mouse, 786
  C. albicans
    infection, immunization against, oral, mouse, 133
    infectivity, B cell knockout mouse, 589
  C. trachomatis, infection, genital tract, lymphocyte phenotype and cytokines, female macaque, 647
  dengue-2 virus vaccine, purified-inactivated, mouse and rhesus monkey models, 1176
  fecal peritoneal infection, GM-CSF vs. G-CSF in, mouse, 790
  G-CSF, effect in pneumococcal pneumonia, cirrhotic rat, 225
  HBV vaccine, against HBsAg, primate model, 1168
  H. capsulatum hsp60, vaccine, mouse, 828
  H. influenzae type b, colonization, infant rat, 1337
  HIV-2 vaccine, canarypox, efficacy and immunogenicity, monkey, 977
  HSV infection, acute, antibody role, neonatal guinea pig, 667
  HTLV-I–induced myelopathy, *pX* and TNF-α genes, local activation, rat, 318
  ICAM-1, host defense, in candidiasis, ICAM 1–deficient mouse, 435
  L. major infection, C12006 blockade effect, mouse, 1303
  L. monocytogenes, infection, lymphokine-activated NK activity, mouse, 1073
  MAC infection, clarithromycin-resistant, ethambutol effect on, beige mouse, 1218
  M. avium infection, IL-12 for, replacement therapy, mouse, 564
  rotavirus infection
    diarrhea, immunity and pathogenicity, mouse, S47
    maternal antibody protection, neonatal swine, 276
  RSV infection, MAb for, rhesus monkey, 256
  S. aureus, methicillin-resistant, infection, prosthetic joint, rabbit, 414
  sepsis, *E. coli,* experimental, neutropenic mouse, 1249
  S. pneumoniae pneumonia, animal models, 507, 994
Antibody
  to CMV, mucosal,387
  to HPV-16, capsid, natural history, among cohort of university women, 927
  to HSV infection, role in HSV latency, 667
  monoclonal
    to HIV V3 loop, mouse model, 866
    to *N. gonorrhoeae* lipooligosaccharide , 1223
    to RSV
      in humans, 463
      rhesus monkey model, 256
    to TNF, in cerebral malaria, 1091
  to *P. falciparum,* prevalence in travelers from Africa, 1376
  to rotavirus
    maternal, neonatal swine model, 276
    serum, fecal, and breast milk, in mother-infant pairs, S22
  to *S. pneumoniae,* repertoire to carbohydrate capsule, 75
Antibody-dependent cellular cytotoxicity, effect of IL-12, in HIV infection, 1105
Arthritis, Lyme, murine, vitamin A effect on, 747
Arylene bis(methylketone) compounds, antimalarial activity, 659
Aspergillus fumigatus, infection, macrophage activity against, 651
Atheroma, detection of *C. pneumoniae,* 893, 895

Bacille Calmette-Guérin, vaccination, percutaneous and intradermal, immune response, 113
Bacteremia, *S. pneumoniae,* in HIV infection, 242
Bacteriuria, asymptomatic, pediatric, IL-6 and IL-8 in, 1080
Biliary atresia, group C rotavirus, human infant liver samples, 8
Biofilm, *S. epidermidis,* polysaccharide intercellular adhesin, 881
Blood transfusion, HIV-1 transmission by, factors in, 26
Bordetella pertussis infection
  or *B. parapertussis,* infection, laboratory diagnosis, 89
  IL-12 and IFN-γ effect, mouse model, 786
  PCR detection, impact on clinical research, 1288
  seroepidemiology, cross-sectional, 896
Borrelia burgdorferi
  infection
    antibody measurement, 346
    DNA detection, by PCR in CSF, 623
    Lyme arthritis, vitamin A effect on, 747
    urban, enhancement by presence of rats, 1108
  sensu lato, isolates, comparison with strain 25015, 1112
  vaccine against, antibody response, in humans and hamsters, 739
Borrelia recurrentis, infection, Jarisch-Herxheimer reaction, pentoxifylline effect in, 627
Borrelia species, urokinase type plasminogen activator and plasminogen binding, 97
Boutonneuse fever, C1168 T cell subsets and cytokine profiles in, 1051

C1168 T cell subsets, in Boutonneuse fever, 1051
Calprotectin, effect, on *C. albicans* growth, 1369
Candida albicans
  growth, effect of calprotectin, 1369
  infection
    fluconazole anti-candida activity, 888
    immunization against, oral, mouse model, 133
    infectivity, B cell knockout mouse model, 589
Candida species, infection, fluconazole vs. nystatin for, after liver transplant, 583
Candida tropicalis, β_1 integrin fibronectin receptor in, 127
Candidiasis, oropharyngeal, in HIV infection, fluconazole for, 821
Cell-mediated immunity, synergy with antifungal chemotherapy, in *C. albicans* infection, 888
Centers for Disease Control and Prevention, Pneumococcal Sentinel Surveillance System, update, drug-resistant *S. pneumoniae,* 986
Cerebrospinal fluid, HIV-1 markers of infection, in children, 288
Chancroid, immunohistochemical analysis, 427
Chlamydia pneumoniae, atherosclerosis, 893, 895
Chlamydia psittaci, infection, chronic, in sheep, 1296
Chlamydia trachomatis infection

genital tract, lymphocyte phenotype and cytokines, female macaque model, 647
scarring, risk and HLA type, case-control study, in Gambia, 643
Chlorine, resistance, in *V. cholerae* O1, 1364
Ciprofloxacin, resistance, of *H. influenzae,* in cystic fibrosis, 1345
Cirrhosis, *S. pneumoniae* pneumonia in, effect of G-CSF, rat model, 225
Clarithromycin resistance
in MAC infection, ethambutol effect on, beige mouse model, 1218
in *M. avium,* mechanism, 354
Coagulase-negative staphylococci, characterization by PFGE, from neonates and children, 1010
Coccidioides immitis, infection, human, cytokines response in, 440
Colitis, *E. histolytica* infection, IgA response, correlation with serum antigen, 157
Corynebacterium diphtheriae, infection, in Russia, 1985–1994, molecular epidemiology, 1064
Cryptococcus neoformans, infection, in HIV infection, subtype analysis, 812
Cryptosporidium parvum infection
experimental, IFN-γ effect in, 229
outbreak, associated with well water, 1372
Cyclosporine, for HIV-1 infection, latent, 850
Cystic fibrosis, *H. influenzae* persistence in, 1345
Cytokines
in *C. immitis,* infection, 440
in *C. trachomatis* infection, genital tract, female macaque model, 647
HSV glycoprotein–elicited, 899
after LPS injection, in vivo, 1356
in MAC-infected human monocytes, PGE_2 production, 806
in *M. tuberculosis,* infection, 431
in *O. volvulus* ocular infection, 380
proinflammatory, in Lyme arthritis, vitamin A effect, 747
Cytomegalovirus
C1249 regulation, on alveolar macrophages, 69
encephalitis, in HIV infection, MIP-1 in CSF, 1098
induction of IgG Fc γ receptor, in endothelial cells, 1151
infection
cytokine production, by bone marrow stromal cells, 913
human, mucosal antibody to, after natural infection and CMV immunization, 387
interstrain variation, day care center children, 606
lactoferrin role in breast milk, 444
pp65 antigenemia, after autologous marrow and blood stem cell transplantation, 907
retinitis, in AIDS, 184, 188, 393
transmission, breast milk, 444
Cytotoxic T lymphocytes
HIV Gag- and EBV-specific CTL precursors, kinetics in HIV-1 infection, 34
response
to canarypox vaccine, against HIV, 734
to HIV-1 infection, 209

Dapsone, prophylaxis failure, due to iron overload, 241, 242
Dengue-2 virus, vaccine, purified-inactivated, immunogenicity and protection, mouse and rhesus monkey models, 1176
Diarrhea
E. coli, enterotoxigenic, colonization factors, in children, in India, 768
microsporidiosis in HIV infection, detection by PCR, 874
rotavirus
infection, S3, S47
vaccine against, 268, S1, S2
US-Japan Conference on Cholera and related Diarrheal Diseases, 451
Didanosine-zidovudine therapy, for HIV-1 infection, in patients with non-SI phenotype, 854
Diphtheria, in Russia, 1985–1994, molecular epidemiology, 1064
Diphtheria-tetanus toxoids–pertussis vaccine
clinical development, S276
coadministration with *H. influenzae* conjugate vaccine, in same syringe, 1341
Dobrava virus, infection, HFRS, genetic detection, in Greek and Albanian patients, 407

Encephalitozoon intestinalis, infection, in duodenal biopsies, detection by PCR, 874
Encephalopathy, HIV, RNA in CSF and zidovudine resistance, in children, 1200
Endocarditis, *S. aureus,* collagen binding in, 83
Endothelial cells, Gelfoam-cultured, penicillin G–induced microbicidal ability, against *S. aureus,* 1001
Endotoxin, *S. abortus equi,* diurnal variation, in host response, human, 1040
Entamoeba histolytica, infection, IgA response, correlation with serum antigen, 157
Enterocytozoon bieneusi, infection, in duodenal biopsies, detection by PCR, 874
Eosinophilia, in HIV-1 infection, 615
Epidemiology
A. baumannii infection, outbreak, in critical care unit, 1279
B. burgdorferi infection, urban, enhancement by presence of rats, 1108
CMV infection, interstrain variation, day care center children, 606
C. parvum infection, outbreak, associated with well water, 1372
E. coli
pathotypes, in children with diarrhea, prevalence, 1124
Vero cytotoxigenic, in dairy farm families, 1021
GAS outbreaks, high-resolution genotyping, 500
GB virus C infection, prevalence, in hepatitis of unknown etiology, in Italy, 181
HBV and HDV coinfection, in outbreaks of hepatitis, in Peruvian Amazon basin, 920
HCV infection, nosocomial transmission, in renal transplant unit, phylogenetic analysis, 177
HGV, parenteral and sexual transmission, 1320
HHV-8, prevalence, among healthy persons in Italy, 668, 669
HIV infection
HIV-positive blood donations from HIV-negative persons, in Thailand, 870
in pregnancy, zidovudine use in, 1207
and STDs, in developing countries, health programs, S162
transmission, 26, 722
vaccine trials, in US homosexual men, feasibility, 954
HPV infection, genital, risk factors for, college women, 679
HPV-16, antibody, capsid, natural history among cohort of university women, 927
H. pylori infection, in children and adolescents, serologic survey, population-based, 1120
HTLV-II infection, peripheral neuropathy, among IDUs, in Spain, 891, 892
HTLV-IIB, endemic, in Argentinean and Paraguayan indians, epidemiology and molecular characterization, 944
influenza outbreaks, in summer, 674
L. pneumophila serogroup 5 infection, nosocomial, implications, 1116
N. gonorrhoeae infection, mass treatment, in female sex workers, in Philippines, S230
P. falciparum infection, antibody to, prevalence in travelers from Africa, 1376
rotavirus infection, S3, S5, S19
S. enterica, subspecies *enterica,* ceftazidime-resistant, outbreak, nosocomial, 1015

S. japonicum infection, population-based chemotherapy, long-term impact, in Philippines, 163
S. pneumoniae infection, antibiotic-resistant, 986, 1352
STD
and behavior, mathematical models, S150
core, development and use of concept, S134
epidemics, topology, S201
epidemiology, S144, S182, S188
prevention, individual- and population-based programs, S248
VZV infection, epidemiology, among young adults, 835
Epstein-Barr virus, infectious mononucleosis, acyclovir and prednisolone for, 324
Errata
Aurelius et al., 1996;174:324–31, 678
Sommerfelt et al., 1996;174:768-76, 1142
Van Voorhis et al., 1996;174:647–50, 1142
Escherichia coli infection
bloodstream, and *K. pneumoniae* infection, ceftazidime-resistant, molecular epidemiology, 529
diarrhea, 246, 451, 675, 676
enterotoxigenic, colonization factors, in children, in India, 768
non-O157 Vero toxin–producing, in HUS, immune response, 1028
non-O157:H7 Shiga toxin–producing, perspective, 1136
pathotypes, in children with diarrhea, prevalence in New Caledonia, 1124
Vero cytotoxigenic, in dairy farm families, 1021
Ethanol, pulmonary clearance effect, in *S. pneumoniae* pneumonia, rat model, 507

Filariasis, Bancroftian, protective immunity in, 598
FK506, for HIV-1 infection, latent, 850
Flagella, use in ELISA, for Lyme disease diagnosis, 346
Fluconazole for
C. albicans infection, 583, 888
candidiasis, in HIV infection, 821
cryptococcosis, in HIV infection, susceptibility, 812
Fluoroquinolone, resistance, of *M. tuberculosis,* association with gyrase mutations, 1127

Ganciclovir, for CMV retinitis, in AIDS, 188
Gastroenteritis, SRSV, outbreaks, in Netherlands, 610
GB virus
infection, prevalence, in hepatitis of unknown etiology, 181
phylogenetic analysis, genetic heterogeneity, 410
Genital herpes, HSV antibody to, relationship to symptoms, 470
Genital ulcer disease, in HIV-1 infection, 445, 446
Giardia lamblia, molecular epidemiology, sequence-based, 233
Glycocalyx, *S. epidermidis,* polysaccharide intercellular adhesin, 881
Glycoprotein B
gene, sequence analysis, interstrain variation, day care center children, 606
groups, CMV, in retinitis, in AIDS, 184
Gonorrhea (See *Neisseria gonorrhoeae* infection)
Granulocyte colony-stimulating factor effect
on gram-positive infection, during granulocytopenia, mouse model, 417
on PMNL function, in cancer chemotherapy–treated children, 800
in pneumococcal pneumonia, cirrhotic rat model, 225
Granulocyte-macrophage colony-stimulating factor, vs. G-CSF, in peritoneal infection, mouse model, 790
Group A streptococci, infection, outbreaks, high-resolution genotyping, 500
Group B streptococci, infection, IL-6 induction by, 332

Haemophilus ducreyi, chancroid, immunohistochemical analysis, 427
Haemophilus influenzae
ciprofloxacin-resistant, persistence, in cystic fibrosis, 1345
colonization, infant rat model, 1337
vaccine, conjugate, coadministration with DTP, in same syringe, 1341
Heat-shock protein A, *H. pylori* infection, immune response, 1046
Heat-shock protein 60, *H. capsulatum,* protective immunity, 828
Helicobacter pylori
infection
in children and adolescents, serologic survey, population-based, 1120
chronic, neutrophil hyporesponsiveness in, 544
by multiple strains, metronidazole resistance in, 631
quantitative culture and histology, 552
response to heat-shock protein A in, 1046
LPS, monocyte activation by, 1255
Helminth vaccine
A. caninum, mouse model, 1380
development, perspective, 1384
Hemolytic uremic syndrome, *E. coli,* non-O157 Vero toxin–producing, immune response, 1028
Hemorrhagic fever with renal syndrome, Dobrava virus, genetic detection, in Greek and Albanian patients, 407
Hepatitis B virus
and HDV, coinfection, in outbreaks of hepatitis, in Peruvian Amazon basin, 920
vaccine, recombinant, primate model, 1168
Hepatitis C virus
cell cultures, contamination of commercial bovine sera with bovine viral diarrheal virus, 1324
infection, antigenic determinants, in NS3 protein, 173
chronic, 842, 1316
cluster, in renal transplant unit, phylogenetic analysis, 177
effect of HIV infection on, in IDUs, 690
IFN-α for, treatment response factors, 1
Hepatitis G virus, parenteral and sexual transmission, 1320
Herpes simplex virus infection
acute, antibody role, neonatal guinea pig model, 667
glycoproteins, T cell recognition, and cytokine production, 899
neonatal, PCR to diagnose and manage, 1162
type 2, reactivation, tk^-, acyclovir-resistant, 476
types 1 and 2, antibody to, relationship to symptoms, 470
Herpes zoster, racial differences, 239, 240
Histoplasma capsulatum, vaccine, hsp60, protective immunity, 828
Hookworm, *A. caninum,* vaccine, mouse model, 1380
Human herpesvirus
type 4, infectious mononucleosis, acyclovir and prednisolone for, 324
type 7, persistence, in healthy subjects, 396
type 8
detection, prior to clinical Kaposi's sarcoma, in HIV infection, 283
DNA sequences, in Kaposi's sarcoma patients, 1101
prevalence, among healthy persons in Italy, 668, 669
Human immunodeficiency virus type 1 infection
$\gamma\Delta$ T cell subsets, in HIV-1 infection, with disseminated MAC infection, 969
ACTG 076, zidovudine use during pregnancy, pattern, 1207
AIDS dementia complex, predictive markers for, 294
candida infection in, fluconazole for, 821
cervical-vaginal shedding during menstruation, 858
CMV
encephalitis in, MIP-1 in CSF, 1098
retinitis in, gB group 2, 184
cryptococcosis in, subtype analysis, 812
diagnosis, population- vs. individual-based, S176
didanosine-zidovudine therapy, in patients with non-SI phenotype, 854

E. coli, enteroadherent, diarrhea, 246
effect, on HCV infection, in IDUs, 690
encephalopathy, RNA in CSF and zidovudine resistance, in children, 1200
eosinophilia in, 615
Gag- and EBV-specific CTL precursors, kinetics, 34
genital ulcer disease in, 445, 446
HIV-positive blood donations from HIV-negative persons, in Thailand, 870
and HTLV-II, coinfection, effects on HIV disease progression, 309
hydroxyurea for, 204
IL-12
effect on lymphocyte proliferative response, in vitro, 483
effect on NK cell cytotoxicity and ADCC, 1105
production in, molecular analysis, 46
immunization with recombinant p17/p24:Ty virus-like particles, 862
influenza vaccine administration, effect on virus load, 1332
in vitro, in monocytes, TNF-modulated, 54
and iron overload, 241, 242
Kaposi's sarcoma in, HHV-8 sequence detection, 283
lamivudine for, in children, phase I/II study, 16
lysis of antigen-expressing cells, by CTL ex vivo, 209
MAC infection in, protection from MAC by prior TB, 1212
M. tuberculosis infection in, effect on HIV disease progression and RNA load, in IDU, 299
multidrug resistance, to nucleoside analogs and nonnucleoside RT inhibitors, 962
neurosyphilis in, diagnosis, by PCR, 219
opportunistic infections, virus load markers in, 401
P. carinii pneumonia
recurrent, genetic diversity, in rRNA operon, 141
TNF-α mRNA in BAL cells, 654
PCR for diagnosis, false-negative, 244
pediatric, 288, 713
pentoxifylline for, in tuberculosis, 727
plasma RNA level, 191, 696, 704
pneumococcal vaccination in, effect on HIV, 1191
pseudouridine and 1-ribosylpyridin-4-one-3-carboxamide, in serum, as predictor of HIV disease progression, 199
replication, in vitro inhibition by β-mercaptoethylamine, 214
socioeconomic impact, S253
S. pneumoniae bacteremia in, in HIV infection, 242
and STDs, S127, S214, S240
TNF-α role in, 63
transmission, 26, 722
vaccine
CTL response in, 734
trials, in US homosexual men, feasibility, 954
V3 loop of gp120, effects of maternal antibody, mouse model, 866
viral kinetics, in lymph nodes vs. plasma, 404
zidovudine
plasma concentrations, systemic and cellular model, 490
in pregnancy, 673
resistance, 195, 448, 845
and stavudine, in combination, intracellular metabolism, 671
Human immunodeficiency virus type 2, infection, vaccine, canarypox, in monkeys, 977
Human papillomavirus infection
genital, risk factors for, college women, 679
type 16, antibody, capsid, natural history, among university women, 927
VLPs, serology, 237, 238, 937
Human T cell leukemia/lymphoma virus type IIB, infection, endemic, in Argentinean and Paraguayan indians, 944
Human T cell lymphotropic virus type I–induced myelopathy, *pX* and TNF-α genes, local activation, rat model, 318
Human T cell lymphotropic virus type II, infection
and HIV-1, effects of coinfection on HIV disease progression, 309
neuropathy, peripheral, among IDUs, in Spain, 891, 892
Hydroxyurea, for HIV-1 infection, 204
Hypervariable region, HCV, sequence analysis, in chronic hepatitis C, 1316

IgG
Fc γ receptor, CMV induction of, in endothelial cells, 1151
prophylaxis, for *Klebsiella* and *Pseudomonas* infections, 537
Infectious Diseases Society of America, US Pfizer HIV/AIDS training programs, 897, 1141
Infectious mononucleosis, acyclovir and prednisolone for, 324
Influenza
outbreaks, in summer, 674
transmission, ferret model, 674
vaccine
effect on HIV-1 load, 1332
tolerance and immunogenicity, in healthy adults, 838
Integrin fibronectin receptor, in *C. tropicalis,* 127
Intercellular adhesion molecule-1
host defense, in candidiasis, ICAM 1–deficient mouse model, 435
rhinovirus effect on T cell proliferation, 1143
Interferon-α, for HCV infection, 1
Interferon-γ
in Boutonneuse fever, 1051
in *B. pertussis* infection, effect, 786
in *C. parvum* infection, effect, 229
production, elicited by HSV glycoproteins, 899
Interleukin-1β, production, in chronic HCV infection, 842
Interleukin-2, production, elicited by HSV glycoproteins, 899
Interleukin-4, production, elicited by HSV glycoproteins, 899
Interleukin-6
in Boutonneuse fever, 1051
in febrile UTI and asymptomatic bacteriuria, pediatric, 1080
induction, by group B streptococci, 332
Interleukin-7, in *M. avium* complex infection, 574
Interleukin-8
in febrile UTI and asymptomatic bacteriuria, pediatric, 1080
induction, by RSV, 262
Interleukin-10
in Boutonneuse fever, 1051
production, elicited by HSV glycoproteins, 899
in *S. pneumoniae* pneumonia, impaired host defense, mouse model, 994
Interleukin-12
in *B. pertussis* infection, effect, 786
in HIV-1 infection
effect on NK cell cytotoxicity and ADCC, 1105
IL-12 effect on lymphocyte proliferative response, in vitro, 483
molecular analysis, 46
for *M. avium* infection, replacement therapy, mouse model, 564
Iron overload, in AIDS, 241, 242
Isoniazid, effect, on *M. tuberculosis,* 1085
IVIG, prophylaxis, for *Klebsiella* and *Pseudomonas* infections, 537
Ixodes dammini, spread by bird migration, role in Lyme disease, 221
Jarisch-Herxheimer reaction, in *B. recurrentis* infection, pentoxifylline effect in, 627

Kaposi's sarcoma, HHV-8 detection in, 283, 1101
Klebsiella pneumoniae infection

ceftazidime-resistant, and *E. coli* bloodstream infection, molecular epidemiology, 529
IgG and IVIG prophylaxis for, 537

Lactobacilli, H_2O_2-producing, correlation with acquisition of vaginal infections, 1058
Lamivudine, for HIV-1 infection, in children, phase I/II study, 16
Laryngitis, *M. catarrhalis,* acute, infection vs. colonization, 636
Legionella pneumophila, serogroup 5, infection, nosocomial, laboratory and epidemiologic implications, 1116
Leishmania major, infection, C12006 blockade effect, mouse model, 1303
Lipooligosaccharide, *N. gonorrhoeae,* 1223, 1238
Lipopolysaccharide
effect on cytokine production, by whole blood, in vivo exposure, 1356
H. pylori, monocyte activation by, 1255
Liposome, for malaria vaccine delivery, 361
Lipoteichoic acid, viridans streptococci, induction of TNF and NO, by murine macrophages, 1348
Listeria monocytogenes infection
lymphokine-activated NK activity, 1073
macrophage activity against, 651
Lyme disease
acrodermatitis chronica atrophicans lesion, etiology, 421
bird migration role, 221
serodiagnosis, 346
spirochetes, in Europe, 421, 424
Lymphocyte, phenotype, in *C. trachomatis* genital tract infection, female macaque model, 647

Macrophage
alveolar, C1249 regulation, by CMV, 69
deactivated, activity against *A. fumigatus* and *L. monocytogenes,* 651
Magnetic resonance imaging, in MRSA prosthetic joint infection, rabbit model, 414
Malaria
cerebral, pediatric, anti-TNF MAb effect, 1091
P. vivax, relapse, molecular analysis of strains, 373
vaccine
SPf66, in African children under intense transmission of *P. falciparum,* 367
sporozoite-based, 361
Meningitis
mumps vaccine–associated, Urabe AMP, genetic variation, 619
pediatric, bacterial, NO role, 120
S. pneumoniae, penicillin-resistant, spread in children, 520
TNF activity in CNS, sTNFR role, 557
Methicillin, resistance, *S. aureus,* prosthetic joint infection, rabbit model, 414
Metronidazole, resistance, in *H. pylori* multiple-strain infection, 631
Microsporidiosis, in HIV infection, detection in duodenal biopsies, by PCR, 874
Monocyte
activation, by *H. pylori* LPS, 1255
chemotactic protein-1, in CSF, in CMV encephalitis, in AIDS, 1098
HIV replication, adhesion molecule–modulated, 54
Moraxella catarrhalis, infection, laryngitis, acute, infection vs. colonization, 636
Mumps virus, vaccine, Urabe AM9, variation in HN gene, 619
Mycobacterium avium complex infection
clarithromycin-resistant, ethambutol effect on, beige mouse model, 1218
in HIV infection, protection from MAC by prior TB, 1212
IL-7 role, 574
of monocytes, human, PGE_2 production, 806
Mycobacterium avium infection
clarithromycin resistance in, mechanism, 354
IL-12 for, replacement therapy, mouse model, 564
Mycobacterium avium–intracellulare complex, infection, disseminated, in HIV-1 infection, $\gamma\Delta$ T cell subset increases, 969
Mycobacterium tuberculosis
infection
immune response to, 431
isoniazid treatment, lipid biosynthetic responses, 1085
latent, effect on HIV disease progression and RNA load, in IDU, 299
multidrug-resistant, fluoroquinolone resistance in, association with gyrase mutations, 1127
virulence, for human macrophage, 105

Neisseria gonorrhoeae
infection, mass treatment, of female sex workers, in Philippines, S230
lipooligosaccharide epitope 2C7, immunogenicity, 1223, 1238
Neisseria meningitidis
infection
TNF-α gene promoter region association, 878
typing methods for, 760
vaccine, conjugate, in UK infants, 1360
Neopterin, in CSF, AIDS dementia complex, predictive marker for, 294
Neurosyphilis, in HIV-1 infection, diagnosis, by PCR, 219
Neutrophil, hyporesponsiveness, in *H. pylori* infection, chronic, 544
Nevirapine, for HIV infection, pediatric, 713
Nitric oxide
in meningitis, bacterial, pediatric, role in, 120
synthase, in murine macrophages, 638
NK cell
activity, in *L. monocytogenes,* infection, mouse model, 1073
cytotoxicity, effect of IL-12, in HIV infection, 1105
Nonnucleoside reverse transcriptase inhibitors, resistance, multidrug, in HIV-1 infection, 962
Nucleoside analogs, resistance, multidrug, in HIV-1 infection, 962
Nystatin, vs. fluconazole, for *Candida* infection, after liver transplant, 583

Onchocerca volvulus
infection, ocular, cytokine reponse, 380
ligands, effect on $\gamma\delta$ T cell subset, 1309
Opportunistic infections, in HIV-1 infection, virus load markers in, 401
Outer surface protein A, vaccine, against *B. burgdorferi* infection, 739

Papillomavirus, human, infection, genital, risk factors for, college women, 679
Papillomavirus type 16
antibody, capsid, natural history, among cohort of university women, 927
VLPs, serology, 237, 238, 937
Penicillin
on Gelfoam blocks, induction of endothelial cell microbicidal activity against *S. aureus,* 1001
resistance, in *S. pneumoniae* infection, 513, 520
Penicillin-binding proteins, *S. pneumoniae,* 884
Pentoxifylline
effect on Jarisch-Herxheimer reaction, in *B. recurrentis* infection, 627
for HIV-1 infection, in tuberculosis, 727
Peptic ulcer disease, *H. pylori,* bacterial counts, 552
Peptidoglycan, signal transduction pathways, 777

Perspective
E. coli, non-O157:H7 Shiga toxin–producing, 1136
helminth vaccine development, 1384
Pertussis
diagnosis, by PCR, impact on clinical research, 1288
historical review and classical vaccine, S259
vaccine, S264, S270, S276, S281, S287, S291
Phorbol myristate acetate, induction of cytokine release, 842
Plasminogen activator, urokinase type, and plasminogen, in borreliae, 97
Plasminogen activator inhibitor 2, monocyte induction by *H. pylori* LPS, 1255
Plasmodium falciparum, malaria
antibody to, prevalence in travelers from Africa, 1376
vaccine for, 361
Plasmodium species, infection, arylene bis(methylketone) compounds for, 659
Plasmodium vivax, malaria, relapse, molecular analysis of strains, 373
Pneumocystis carinii infection
pneumonia
recurrent, genetic diversity, in rRNA operon, in HIV infection, 141
TNF-α mRNA in BAL cells, in HIV infection, 654
prophylaxis failure, due to iron overload, in HIV infection, 241, 242
Pneumonia
P. carinii, recurrent, in HIV infection, genetic diversity, in rRNA operon, 141
RSV, community-acquired,456
S. pneumoniae
in cirrhosis, G-CSF effect on, rat model, 225
IL-10 role in host defense, mouse model, 994
Poliovirus, vaccines, analysis for HIV and SIV, 1185
Polymerase chain reaction
culture, and serology, to diagnose *Bordetella* infections, in immunized population, 89
to detect
B. burgdorferi, in CSF, 623
B. pertussis, 1288
HHV-8, 283, 396, 668, 669
HIV-1, false-negative, 244
HSV, neonatal infection, 1162
T. pallidum infection, in CNS, in HIV-1 infection, diagnosis, 219
RAPD, to detect *H. pylori,* 631
repetitive element–based, for *N. meningitidis* typing, 760
Polymorphonuclear leukocyte, function, in cancer chemotherapy, 800
Polysaccharide, *S. epidermidis,* intercellular adhesin, 881
Praziquantel, for *S. japonicum* infection, population-based chemotherapy, long-term impact, in Philippines, 163
Prostaglandin E_2, production by MAC-infected human monocytes, cytokine expression, 806
Pseudomonas aeruginosa, infection, IgG and IVIG prophylaxis for, 537
Pseudouridine, serum concentration, as predictor of HIV disease progression, 199
Pulsed-field gel electrophoresis, to characterize coagulase-negative staphylococci, from neonates and children, 1010

Random amplification polymorphic DNA PCR, for *H. pylori,* 631
Repetitive element–based polymerase chain reaction, for *N. meningitidis* typing, 760
Respiratory syncytial virus infection
induction of IL-8, 262
MAb against
in humans, 463
rhesus monkey model, 256
pneumonia, community-acquired, 456
Restriction fragment length polymorphisms, *S. pneumoniae,* 884
Retinitis, CMV, in Aids, 184, 188, 393
Reverse transcriptase, mutation, in zidovudine resistance, in HIV-1 infection, 448
Rhinovirus, effect on T cell proliferation, 1143
RNA
group C rotavirus, detection, in infants with biliary atresia, 8
plasma, in HIV infection, prognostic value, 696, 704
Rotavirus infection
antibody in, mother-infant pairs, S22
diarrhea, S3, S47
genotyping, S30
group C, detection in liver samples, in extrahepatic biliary atresia, in infants, 8
immunity, in humans and in mice, S51
immunology, S59
impact, in Venezuela, S19
maternal antibody protection, neonatal swine model, 276
molecular biology advances, S37
replication, as determinant of intestinal response, 1328
from research to vaccine, S1
summary, of fifth rotavirus vaccine workshop, S2
in UK, S5
vaccine, 268, S1, S2, S5, S30, S37, S65, S73, S81, S88, S93, S98, S107, S112, S118
RSHZ19, MAb against RSV, pharmacokinetics, in humans, 463

Salmonella abortus equi, endotoxin, diurnal variation, in host response, human, 1040
Salmonella enterica, subspecies *enterica,* ceftazidime-resistant, outbreak, nosocomial, 1015
Salmonella species, infection, pathogenesis, vaccines for, 451
Schistosoma japonicum, infection, population-based chemotherapy, long-term impact, in Philippines, 163
Schistosoma mansoni infection
hepatosplenic, association with HLA-DQB1*0201, 1131
Th1-like immune response, impaired, 677
SDZ NIM811, for HIV-1 infection, latent, 850
Sepsis, *E. coli,* experimental, neutropenic mouse model, 1249
Sexually transmitted disease
and behavior, mathematical models, S150
core, development and use of concept, S134
in developing countries, health programs, S162
epidemics, topology of, S201
eradication, in China, S223
and HIV infection, S214, S127, S240
prevention, individual- and population-based programs, S248
risk, S144, S182
transmission, study design, S188
Small round-structured viruses, gastroenteritis outbreaks, molecular epidemiology, in Netherlands, 610
Sorivudine, for varicella-zoster infection, 249
SPf66 malaria vaccine, in African children under intense transmission of *P. falciparum,* 367
Staphylococcus aureus
endothelial cell microbicidal activity against, on Gelfoam blocks, 1001
infection
endocarditis, collagen binding in, 83
methicillin-resistant, prosthetic joint, rabbit model, 414
Staphylococcus, enterotoxin A, vaccine, receptor-binding mutants, 338
Staphylococcus epidermidis, biofilm, polysaccharide intercellular adhesin, 881
Stavudine, and zidovudine, combination, for HIV infection, intracellular metabolism, 671, 672

Streptococcus pneumoniae
infection
antibiotic-resistant, 513, 520, 986, 1352
antibody repertoire to carbohydrate capsule, 75
bacteremia, in HIV infection, 242
epidemiology, in California, implications for conjugate vaccine trial, 752
pneumonia, 225, 507, 994
penicillin-binding proteins, 884
vaccine, 752, 1191, 1271
Streptococcus pyogenes, infection, outbreaks, high-resolution genotyping, 500

T cell
γΔ subset, increases, in HIV-1 infection, with disseminated MAC infection, 969
proliferation, rhinovirus effect on, 1143
recognition of HSV glycoprotein, 899
Toxic shock syndrome toxin-1, glycine residue 31, critical for binding to MHC class II molecules, 1261
Treponema pallidum, infection, CNS, in HIV-1 infection, diagnosis, by PCR, 219
Trichinella nativa, infection, associated with cougar jerky consumption, 663
Tumor necrosis factor, MAb to, in cerebral malaria, 1091
Tumor necrosis factor-α
in Boutonneuse fever, 1051
gene promoter region, association with death from meningococcal disease, 878
in HIV-1 infection
inhibition by chimeric MAb, 63
with tuberculosis, 727
in meningitis, sTNFR role, 557
mRNA, in BAL cells, from HIV-infected persons with *P. carinii* pneumonia, 654
production
in chronic HCV infection, 842
by murine macrophages, induction by lipoteichoic acid, 1348
tyrosine kinase effect, murine macrophages, 638
Tyrosine kinase inhibitors, effects on TNF and iNOS production, in murine macrophages, 638

Ulcer, genital, *H. ducreyi,* immunohistochemical analysis, 427
United States–Japan Conference on Cholera and related Diarrheal Diseases, 451
Urinary tract infection, pediatric, febrile, IL-6 and IL-8 in, 1080

Vaccine against
A. caninum, mouse model, 1380
B. burgdorferi, antibody response, in humans and hamsters, 739
BCG, percutaneous and intradermal, immune response, 113
dengue-2 virus, purified-inactivated, mouse and rhesus monkey models, 1176
diphtheria-tetanus toxoids–pertussis, coadministration with *H. influenzae* conjugate vaccine, in same syringe, 1341
diphtheria, tetanus, acellular pertussis, and hepatitis B, clinical development, S298
HBsAg, primate model, 1168
H. capsulatum, hsp60, mouse model, 828
helminth, 1380, 1384
H. influenzae conjugate, 1341, S302
HIV-1, 734, 866, 954
HIV-2, canarypox, in monkeys, 977
influenza A, tolerance and immunogenicity, in healthy adults, 838
malaria, in African children under intense transmission of *P. falciparum,* 367
mumps, Urabe AM9, variation in HN gene, 619
N. meningitidis, conjugate, in UK infants, 1360
pertussis, S259, S264, S270, S276, S281, S287, S291, S295, S298, S302, S306, S310, S314, S320, S324, S330, S335, S342
rotavirus, 268, S1, S2, S5, S30, S37, S65, S73, S81, S88, S93, S98, S107, S112, S118
S. pneumoniae infection, 75, 752, 1271
Vaccines
combined, future, S295
superantigen, receptor-binding mutants, 338
Varicella
epidemiology, among young adults, 835
racial differences and age of onset, 239, 240
sorivudine for, 249
Vibrio cholerae O1, chlorine-resistent form, virulence, 1364
Viridans streptococci, lipoteichoic acid, induction of TNF and NO, by murine macrophages, 1348
Virulence, *M. tuberculosis,* in mouse and human macrophages, 105
Virus-like particles, in rotavirus vaccine, subunit, S88, S98
Vitamin A, deficiency, effect on murine Lyme arthritis, 747

Wucheria bancrofti, infection, protective immunity in, 598

Zidovudine for HIV infection
in pregnancy, 673, 1207
resistance, 195, 448, 671, 672, 696, 845, 1200
Zidovudine-didanosine, for HIV-1 infection, in patients with non-SI phenotype, 854